These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31442328)

  • 1. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 4. The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil.
    Armengot-Carbó M; Nagore E; García-Casado Z; Botella-Estrada R
    J Am Acad Dermatol; 2018 May; 78(5):920-926.e4. PubMed ID: 29307636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric melanoma: the whole (genome) story.
    Pappo AS
    Am Soc Clin Oncol Educ Book; 2014; ():e432-5. PubMed ID: 24857134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
    Geiger CE; Mrabet-Dahbi S; Berger I
    Melanoma Res; 2024 Feb; 34(1):85-87. PubMed ID: 38127894
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations.
    Colombino M; Paliogiannis P; Pagliarello C; Cossu A; Lissia A; Satta R; Mazzoni L; Magi S; Sini MC; Manca A; Casula M; Doneddu V; Palmieri G; Stanganelli I
    Eur J Dermatol; 2018 Apr; 28(2):149-156. PubMed ID: 29180316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
    Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
    Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
    Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
    J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
    Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
    Neville G; Marzario B; Shilling D; Hand CK; Heffron C
    Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.